Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients

Hepato-Gastroenterology

Volumn 54, Issue 76, 2007, Pages 1074-1079

  Gavalas, Emmanuel ^a   Kountouras, Jannis ^a,b   Stergiopoulos, Christos ^a   Zavos, Christos ^a   Gisakis, Dimitrios ^a   Nikolaidis, Nikolaos ^a   Giouleme, Olga ^a   Chatzopoulos, Dimitrios ^a   Kapetanakis, Nikolaos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Department of Medicine ^*  (Greece)

Author keywords

Anti TNF ; Infliximab; Steroid dependent; Ulcerative colitis

Indexed keywords

INFLIXIMAB; METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING SYNDROME; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; SIDE EFFECT; SWEATING; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED;

EID: 34347335820     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F: Immunoregulation in the gut: success and failures in human diseases. Gut 2002; 50(Suppl 3):III60-III64.
2. Edwards FC, Truelove SC: The course and prognosis of ulcerative colitis. Part I and II: Short term and long-term prognosis. Gut 1963; 4:299-315.
3. Farmer RG, Easley KA, Rankin GB: Clinical patterns, natural histpry, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993; 38:1137-1146.
4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255-260.
5. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, Present DH, Rutgeerts P, Scholmerich J, Stange EF, Sutherland LR: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122:512-530.
6. Banerjee S, Peppercorn MA: Inflammatory bowel disease. Medical therapy of specific clinical presentations. Gastroenterol Clin North Am 2002; 31:185-202.
7. Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, Schroeder TK: Ileal pouch-anal anastomosis complications and function in 1005 patients. Ann Surg 1995;222:120-127.
8. McIntyre PB, Pemberton JH, Wolff BG, Beart RW, Dozois RR: Comparing functional results one year and ten years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Dis Colon Rectum 1994; 37:303-307.
9. Kountouras J, Zavos C, Chatzopoulos D: Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. J Cell Mol Med 2004; 8:317-328.
10. Hanauer SB: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12(Suppl 1):S3-S9.
11. Guimbaud R, Bertrand V, Chauvelot-Moachon L, Quartier G, Vidon N, Giroud JP, Couturier D, Chaussade S: Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol 1998; 93:2397-2404.
12. Shen EH, Das KM: Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 2004; 38:741-745.
13. Kountouras J, Zavos C, Chatzopoulos D: Anti-tumor necrosis factor therapy for ulcerative colitis. Gastroenterology 2005; 129:1138-1139.
14. Reimund JM, Wittersheim C, Dumont S, Muller CD, Baumann R, Poindron P, Duclos B: Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16:144-150.
15. Hadziselimovic F, Emmons LR, Gallati H: Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. Gut 1995; 37:260-263.
16. Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R: Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 1997; 40:628-633.
17. Schreiber S: Inflammatory bowel disease: immunologic concepts. Hepatogastroenterology 2000; 47:15-28.
18. Ferkolj I, Ihan A, Markovic S: CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease. Hepatogastroenterology 2005; 52:1128-1133.
19. Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tozun N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dokmeci A: Clinical outcome of Crohn's disease treated with infliximab. Hepatogastroenterology 2003; 50:952-956.
20. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
21. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflammatory Bowel Dis 2001; 7:83-88.
22. Su C, Salzberg BA, Lewis JD, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR: Efficacy of antitumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97:2577-2584.
23. Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M: Infliximab for treatment of steroid refractory ulcerative colitis. Dig Liver Dis 2002; 34:631-634.
24. Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M: Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002; 34:626-630.
25. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52:998-1002.
26. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128:1805-1811.
27. Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 24:2-6.
28. Lopez-Sanroman A, Bermejo F, Carrera E, Garcia-Plaza A: Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther 2004; 20:161-166.
29. Walmsley RS, Ayres RC, Pounder RE, Allan RN: A simple clinical colitis activity index. Gut 1998; 43:29-32.
30. Seo M, Okada M, Maeda K, Oh K: Correlation between endoscopic severity and the clinical activity in ulcerative colitis. Am J Gastroenterology 1998; 93:2124-2129.
31. Higgins PD, Schwartz M, Mapili J, Zimmermann EM: Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 2005; 100:355-361.
32. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M: Infliximab Efficacy in Pediatric Ulcerative Colitis. Inflamm Bowel Dis 2005; 11:213-218.
33. Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA: Infliximab in the treatment of medically refractory indeterminate Colitis. Aliment Pharmacol Ther 2003; 18:741-747.
34. Russell GH, Katz AJ: Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004; 39:166-170.
35. Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, Janczewska I, Sjoqvist U, Lofberg R: Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53:849-853.
36. Pharand C, Palisaitis DA, Hamel D: Potential anaphylactic shock with abciximab readministration. Pharmacotherapy 2002; 22:380-383.
37. Ochsenkuhn T, Sackmann M, Goke B: Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004; 16:1167-1171.
38. Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA: National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 77:870-882.
39. Clowes JA, Peel N, Eastell R: Glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2001; 13:326-332.
40. Caesar I, Gross V, Roth M, Andus T, Hohenberger W, Scholmerich J: Steroid-induced myopathy in left-sided ulcerative colitis. Successful treatment and continued therapy with the topical steroid budesonide [German]. Med Klin (Munich) 1997; 92:358-362.
41. Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A: Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004; 8:231-233.
42. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476.
43. Hermida-Rodriguez C, Cantero Perona J, Garcia-Valriberas R, Pajares Garcia JM, Mate-Jimenez J: High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease. Hepatogastroenterology 1999; 46:2265-2268.
44. Sandborn WJ: Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol Belg 2001; 64:201-204.
45. D'Haens G: Infliximab for ulcerative colitis: finally some answers. Gastroenterology 2005; 128:2161-2164.
46. Ezell TN, Maloney N, Githua JW, Taylor LD: Exposure to the anti-TNF-alpha drug thalidomide induces apoptotic cell death in human T leukemic cells. Cell Mol Biol (Noisy-le-grand) 2003; 49:1117-1124.
47. Morisaki T, Matsunaga H, Beppu K, Ihara E, Hirano K, Kanaide H, Mori M, Katano M: A combination of cyclosporin-A (CsA) and interferon-gamma (INF-gamma) induces apoptosis in human gastric carcinoma cells. Anticancer Res 2000; 20:3363-3373.
48. Lim SJ, Simeone AM, Kim CK, Tari AM: Cyclosporine A enhances the apoptotic effects of N-(4-hydroxyphenyl) retinamide in breast cancer cells. Int J Cancer 2002; 101:243-247.